吡格列酮治疗胰岛素抵抗合并顽固性高血压56例临床效果观察  

Clinical effect observation of pioglitazone on 56 cases of insulin resistance combined with resistant hypertension

作　　者：赵颖波[1] 

机构地区：[1]云南省华坪县医院内分泌科,云南华坪674800

出　　处：《中国医药科学》2013年第4期86-87,共2页China Medicine And Pharmacy

摘　　要：目的观察吡格列酮治疗胰岛素抵抗合并顽固性高血压的临床疗效。方法将2009年2月～2011年8月来院就诊的110例胰岛素抵抗合并顽固性高血压患者随机分成两组,治疗组56例,每天加口服吡格列酮,54例对照组:坚持使用原用的降压药,不改变其生活方式。所有患者均在加用药之前和加用药8周后检测其血压、FINS、FBG,并进行比较分析。结果治疗组患者的胰岛素的抵抗指数值以SBP、DBP、FPG、FINS,同治疗前相比有明显下降,差异有统计学意义(P<0.01)。疗效明显优于对照组。结论吡格列酮不仅能够明显降低患者空腹血糖,还有降低血清胰岛素水平的以及降低血压良好效果,从而有效改善患者胰岛素抵抗作用,适合推广应用到临床。Objective To observe the clinical effect of pioglitazone on insulin resistance combined with resistant hypertension. Methods 110 Cases of IRRH patients who were admitted into our hospital from Feb.2009 to Aug.2011 were divided into two groups randomly. 54 cases of control group patients insist to use antihypertensives and maintain the original life style, while 56 cases of treatment group patients were treated with pioglitazone additionally. Finally, the blood pressure, FINS, FBG levels of all patients were measured and comparatively analyzed before and after 8 weeks of treating with additional drugs. Results Compared with the values before treatment, HOMA-IR, SBP, DBP, FPG, FINS levels of treatment group patients were significantly decreased （P 〈 0.01 ）, and the effect was superior to the control group. Conclusion Pioglitazone not only can significantly decrease the FBG level, but also can decrease the FINS and blood pressure level. In addition, pioglitazone can improve the effect of insulin resistance and has a promoted value in clinical therapy.

关 键 词：胰岛素抵抗 顽固性高血压 吡格列酮 

分 类 号：R544.1[医药卫生—心血管疾病] R587[医药卫生—内科学]